Assessing treatment effect in pancreatic cancer

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 1, 2012, Pages 100-109

  Hartman, Douglas J ^a,b   Krasinskas, Alyssa M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; FIBROSIS; HUMAN; MULTIMODALITY CANCER THERAPY; NECROSIS; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FIBROSIS; HUMANS; NECROSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84856060945     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0144-RA     Document Type: Review

References (54)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7): 1727-1733.
3. NCCN Pancreatic Cancer Panel. Pancreatic Adenocarcinoma. Fort Washington, PA: National Comprehensive Care Network Inc; 2011. NCCN Clinical Practice Guidelines in Oncology; version 2.2011.
4. Bilimoria KY, Bentrem DJ, Ko CY, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173-180. (Pubitemid 47196512)
5. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991;161(1):120-124; discussion 124-125.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
7. Warshaw AL, Swanson RS. Pancreatic cancer in 1988: possibilities and probabilities. Ann Surg. 1988;208(5):541-553. (Pubitemid 18267693)
8. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751-1756.
9. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999; 65(7):618-623; discussion 623-624.
10. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: An outcomes trial. Cancer. 2000;89(2):314-327. (Pubitemid 30489879)
11. White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12(3):214-221. (Pubitemid 40568908)
12. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221(6):721-731; discussion 731-733.
13. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg. 1993;217(2):144-148. (Pubitemid 23059285)
14. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience. Ann Surg. 1997;225(5): 621-633; discussion 633-636.
15. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973: analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37(3):1519-1524.
16. Douglass HO Jr, Nava HR, Panahon A, et al; Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987; 59(12):2006-2010. (Pubitemid 17077780)
17. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899-903; erratum Arch Surg. 1986;121(9):1045. (Pubitemid 15040883)
18. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776-782; discussion 782-784.
19. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15(3):928-937. (Pubitemid 27106274)
20. Boz G, De Paoli A, Roncadin M, et al. Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma. Tumori. 1991;77(1):61-64.
21. Cerny T, Martinelli G, Goldhirsch A, et al. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol. 1991;117(suppl 4):S135-S138.
22. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593-600. (Pubitemid 26285639)
23. Moore MJ. Pancreatic cancer: what the oncologist can offer for palliation. Can J Gastroenterol. 2002;16(2):121-124. (Pubitemid 34406662)
24. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335-1339.
25. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009;20(8):1387-1396.
26. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5(2):121-130. (Pubitemid 33652049)
27. Sasson AR, Wetherington RW, Hoffman JP, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34(2-3):121-128.
28. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3487-3495.
29. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4): e1000267. doi:10.1371/journal.pmed.1000267.
30. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206(5):833-846; discussion 846-848.
31. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619-627.
32. Roy R, Maraveyas A. Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist. 2010;15(3):259-269.
33. Washington K, Berlin J, Branton P, et al. Protocol for the Examination of Specimens From Patients With Carcinoma of the Exocrine Pancreas: Protocol Applies to All Endocrine Tumors of the Pancreas. Northfield, IL: College of American Pathologists; 2010.
34. Ishikawa O, Ohhigashi H, Teshima T, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol. 1989;40(3):143-151. (Pubitemid 19078760)
35. Pendurthi TK, Cooper HS, Young NA, et al. Histopathologic effects of preoperative chemoradiotherapy on pancreatic carcinoma [abstract]. Gastroenterology. 1996;110(4):1410.
36. Le Scodan R, Mornex F, Partensky C, et al. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. Am J Clin Oncol. 2008;31(6):545-552.
37. Shimosato Y, Oboshi S, Baba K. Histologic evaluations of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol. 1971;1(1):19-35.
38. Kumar V, Abbas AK, Fausto N. Cellular adaptations, cell injury and cell death. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Saunders Elsevier; 2005:21.
39. Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008; 248(6):1014-1022.
40. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20(10):2537-2544. (Pubitemid 34525741)
41. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8(2):123-132. (Pubitemid 32199408)
42. Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995;169(1):71-77; discussion 77-78.
43. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12(1):19-23. (Pubitemid 27138353)
44. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002;94(4):1121-1130. (Pubitemid 34150868)
45. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347-1355. (Pubitemid 40410728)
46. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73(11):2680-2686. (Pubitemid 24166250)
47. Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141-146. (Pubitemid 41113116)
48. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22(12):1555-1563.
49. Cho JH, Faragher IG. Tumor regression grade and rectal cancer. Dis Colon Rectum. 2010;53(3):362; author reply 362-363.
50. Bluemke DA, Cameron JL, Hruban RH, et al. Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology. 1995;197(2):381-385.
51. Saisho H, Yamaguchi T. Diagnostic imaging for pancreatic cancer: computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas. 2004;28(3):273-278. (Pubitemid 38437322)
52. Soriano A, Castells A, Ayuso C, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol. 2004;99(3):492-501. (Pubitemid 38524129)
53. Adsay NV, Basturk O, Altinel D, et al. The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment. Mod Pathol. 2009;22(1):107-112.
54. Tomlinson JS, Jain S, Bentrem DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg. 2007;142(8):767-774; discussion 773-774.